Home / News / Research


MDF Research Fellow Profile: Dr. Melissa Dixon

Dr. Dixon at the University of Utah has been awarded a 2016-2017 postdoctoral fellowship for her research applying fMRI to evaluate connectivity networks in the brains of children with congenital-onset myotonic dystrophy (CDM). Read more here about the work of Dr. Dixon and her colleagues.

MDF Welcomes Dr. John Porter as Interim Chief Science Officer

Dr. John Porter, former Program Director of Neuromuscular Disease at the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH), has joined MDF as its Interim Chief Science Officer. Dr. Sharon Hesterlee, who formerly filled this position, will remain active as a member of MDF’s Scientific Advisory Committee.

Dr. Charles Thornton Wins Prestigious Javits Award

Dr. Charles Thornton, neurologist at the University of Rochester Medical Center and MDF Scientific Advisory Committee member, has been awarded a Javits Neuroscience Investigator Award from the National Institutes of Health to further his research on muscular dystrophy. Read more about this very distinguished award for “exceptional” investigators and the important work Dr. Thornton is doing here.

University of Iowa Launches Brain Imaging Study

The University of Iowa has been awarded a grant by the National Institute of Neurological Disorders and Stroke (NINDS) to fund a 3-year longitudinal study of adults with a family history of DM1. Learn more about the study and how to participate in this article.


Industry Corner: Cloud Pharmaceuticals

Cloud Pharmaceuticals, a cloud-based drug design and development company, is interested in potential collaborations around myotonic dystrophy targets.

Research Fellow Profile: Dr. Ian DeVolder

The UK-based Wyck Foundation, in partnership with MDF, has awarded a 2016-2017 postdoctoral fellowship to Dr. Ian DeVolder at the University of Iowa to study CNS-related impacts of DM1.

University of Florida - Sanofi Collaboration Receives DM Drug Screening Grant

In a ground-breaking academic and pharmaceutical company collaboration, Sanofi-Aventis and the University of Florida will screen for new drugs to treat DM1 and DM2. Read the full article here.

Ionis Pharmaceuticals Seeks Trial Participants for DM1 Treatment

Ionis Pharmaceuticals is currently seeking trial participants to evaluate an experimental DM1 drug, IONIS-DMPKrx, that may help modify the disease rather than just treat the symptoms.

Multi-Disciplinary Approach Needed for Congenital and Childhood DM Care

The results of a new MDF-funded study on the impact of congenital myotonic dystrophy are now available from Dr. Nicholas Johnson of the University of Utah and colleagues. The high frequency of social and cognitive issues in their findings underline the need for a multi-disciplinary approach to care. 

The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study

Many common DM symptoms become more severe during pregnancy, and women with DM have higher than average miscarriage rates, according to a study commissioned by MDF that examined data from the Myotonic Dystrophy Family Registry and the National Registry for DM and FSHD. Read a summary of the findings written by Katharine Hagerman, PhD, Research Assistant at Stanford University.


© Myotonic Dystrophy Foundation. All rights reserved.